Evolent Health generated $496.2 million in revenue for the quarter ended March 31, 2026, up from $483.6 million a year earlier. Net loss attributable to common shareholders improved to $(26.6) million, narrowing the loss margin to 5.4% from 14.9%, while adjusted EBITDA declined to $22.1 million, yielding a 4.4% margin.

During Q1, Evolent signed two new healthcare agreements: an advanced imaging solution contract covering approximately 4.5 million lives across Commercial, Medicaid and Medicare lines, and an oncology and cardiology services expansion expected to generate over $200 million in annual revenue. Both agreements are subject to state regulatory approvals and are scheduled to commence in the third quarter.

CEO Seth Blackley highlighted on-time oncology launches with Highmark and Aetna and emphasized AI-driven growth opportunities as priorities through 2027. Evolent ended Q1 with $142.0 million in cash and cash equivalents and is focused on extending its market leadership in complex specialty care while meeting commitments to shareholders, employees and customers.